Physician profile
Patty E Hildreth
NPI 1679573893
$6,645.83
in general payments reported to CMS, 2019-2025
20 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $606 · 2022: $1,166 · 2023: $1,080 · 2024: $1,890 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,873.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $799.91 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $778.36 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $731.64 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $601.43 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $544.31 | 2021-2025 | Rexulti, Brintellix |
| Neurocrine Biosciences, INC. | $517.12 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $490.64 | 2022-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $435.39 | 2021-2024 | Qelbree |
| Abbvie INC. | $382.47 | 2024-2025 | |
| Corium, LLC | $312.91 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $303.71 | 2021-2025 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $280.39 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $158.00 | 2022-2025 | Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $98.88 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $58.61 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $43.01 | 2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $42.84 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $34.97 | 2024-2025 | Xelstrym, Secuado |
| Indivior INC. | $16.29 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $14.95 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patty Hildreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.